ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

作者：Wei J; Zou Z; Qian X; Ding Y; Xie L; Sanchez J J; Zhao Y; Feng J; Ling Y; Liu Y; Yu L; Rosell R; Liu B^*

来源：British Journal of Cancer, 2008, 98(8): 1398-1402.

DOI：10.1038/sj.bjc.6604317

• ERCC1
• TS
• advanced gastric cancer
• FOLFOX

Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum chemotherapy. Excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were assessed in advanced gastric cancer tumour samples using real-time quantitative PCR in 76 patients treated with a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen. Median survival time in patients with low ERCC1 levels was significantly longer than in those with high levels (15.8 vs 6.2 months; P < 0.0001). Patients with high TS levels had longer survival than those with low levels (12.2 vs 10.1 months; P = 0.01). Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1 months (P < 0.0001). The hazard ratio for patients with high ERCC1 expression was 9.4 (P < 0.0001). In patients with high mRNA levels of ERCC1, alternative chemotherapy regimens should be considered.

• 出版日期2008-4-22
• 单位苏州大学; 南京医科大学; 南京大学; 宿州学院